EUS-guided PSE in Combination With EUS-guided Treatment of Varices for Patients With Portal Hypertension

• Status: Recruiting
• Trial end date: 2022-01-05
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to evaluate the efficiency of EUS-guided combination therapy (EUS-guided PSE + EUS-guided treatment of varices) to EUS-guided treatment of varices alone in cirrhotic patients with portal hypertension who have developed gastroesophageal variceal hemorrhage and accompanied with hypersplenism.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tongji Hospital

Criteria

Inclusion Criteria:

• At the risk of gastroesophageal variceal hemorrhage; Acute gastroesophageal variceal hemorrhage; Hematemesis and/or melena resulted from gastroesophageal variceal hemorrhage of liver cirrhosis in the past.

• Hypersplenism is indicated by either abdominal ultrasound or CT image showing splenic enlargement or splenomegaly and CBC test showing deficiency of one or more blood cell lines.

• Consent form must be signed by patients or their guardians before entering the test.

Exclusion Criteria:

• History of liver surgery or spleen surgery and liver cancer

• Coagulopathy (INR > 1.5) or having been taken oral anticoagulation agents such as aspirin, warfarin, etc. in the past week.

• Existence of gastrointestinal endoscopic therapy contraindication; Hemorrhagic shock has not be corrected; Hepatic encephalopathy; Moderate to severe ascites, Poor liver function (Child - Pugh class C).

• Severe cardiorespiratory dysfunction, including sinus bradycardia, bronchial asthma, chronic obstructive pulmonary disease, heart failure, and atrioventricular block

• Pregnant women and nursing mothers.

• Absence of informed consent